Pleomorphic adenoma of Krause's gland in lower lid.

J. Saini,A. Mukherjee,P. Naik

1985-05-01

Indian Journal of Ophthalmology

Abstract:

What problem does this paper attempt to address?

Combination of Anlotinib and Sintilimab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: a Single-Arm Prospective Study

Tianxiao Wang,Jiaxin Wang,Yabing Zhang,Yuntao Song,Guohui Xu,Bin Zhang

DOI: https://doi.org/10.1097/cad.0000000000001660

2024-01-01

Anti-Cancer Drugs

Abstract:To investigate whether blocking both programmed cell death protein and vascular endothelial growth factor receptor could offer superior anticancer activity in these patients without compromising safety. In this study, patients were administered oral anlotinib (12 mg/day) on days 1–14 and intravenous sintilimab (200 mg) on day 1 of a 3-weekly cycle. The primary endpoints included the objective response rate and disease control rate. The secondary endpoints included overall survival (OS) and safety. Ten eligible patients were enrolled between June 2019 and May 2022, and eight patients underwent radiographic assessments. The results showed an objective response rate of 50% (partial and complete response in four and zero patients, respectively) and a disease control rate of 100%; four patients demonstrated stable disease for at least 8 weeks. The median OS was 4.37 (in our study, the score was 7), and the OS rate at 12 months was 37.5%. The Kaplan–Meier survival curve showed that the group with high blood glucose levels had a significantly shorter duration of survival than those with normal blood glucose levels. Adverse events of grade 3 and higher occurred in 50% of patients, and the most common severe adverse events included tumor pain (50%), hypertension (37.5%), tumor hemorrhage (25%), and decreased appetite (25%). The combination of anlotinib and sintilimab showed promising efficacy in controlling tumor size. However, the disappointing OS rate suggests that anti-vascular endothelial growth factor receptor agents should be used cautiously after radical radiation therapy. The combination used in this study demonstrated a toxicity profile comparable to that of other agents used in this setting. These findings warrant further investigation into the potential clinical utility of this combination.
Basal cell carcinoma, syringocystadenoma papilliferum, trichilemmoma, and sebaceoma arising within a nevus sebaceus associated with pigmented nevi.

Yan Wang,Wenbo Bu,Hao Chen,Mengli Zhang,Xue‐si Zeng,Liang Zhao,Fang Fang

DOI: https://doi.org/10.1111/j.1524-4725.2011.02163.x

2011-12-01

Dermatologic Surgery

Abstract:Nevus sebaceus of Jadassohn is a hamartoma that commonly arises at birth or in early childhood and has a well-documented potential to develop a variety of benign and, less commonly, malignant neoplasms of epidermal and adnexal origins. Neoplastic transformation occurs with an estimated incidence of 10% to 30%, and risk of disease increases with age. Nevus sebaceus usually presents as a single yellowish plaque devoid of hair. The natural history of the disease is often divided into three phases: infancy, puberty, and adulthood. Most postpubertal neoplasms arise from the fourth to the seventh decades. Two neoplasms may occasionally arise within the same lesion, but it is rare for three or more neoplasms to occur in a nevus sebaceus simultaneously. Here, we report a patient with nevus sebaceus with four tumors simultaneously occurring in a single lesion— basal cell carcinoma (BCC), syringocystadenoma papilliferum, trichilemmoma, and sebaceoma— associated with widespread nevi in the ipsilateral limb and trunk.
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

Priyanka Sharma,Vandana G. Abramson,Anne O'Dea,Lauren Nye,Ingrid Mayer,Harsh B. Pathak,Marc Hoffmann,Shane R. Stecklein,Manana Elia,Sharon Lewis,Jecinta Scott,Jilliann A. De Jong,Yen Y. Wang,Rachel Yoder,Kelsey Schwensen,Karissa Finke,Jaimie Heldstab,Stephanie LaFaver,Stephen K. Williamson,Milind A. Phadnis,Gregory A. Reed,Bruce F. Kimler,Qamar J. Khan,Andrew K. Godwin

DOI: https://doi.org/10.1158/1078-0432.CCR-20-4879

IF: 13.801

2021-07-15

Clinical Cancer Research

Abstract:Purpose: PIK3CA mutations are common in breast cancer and promote tumor progression and treatment resistance. We conducted a phase I/II trial of alpelisib (α-specific PI3K inhibitor) plus nab-paclitaxel in patients with HER2-negative metastatic breast cancer (MBC). Patients and Methods: Eligible patients had HER2-negative MBC with any number of prior chemotherapies. Phase I was 3+3 dose-escalation design with three dose levels of alpelisib (250, 300, and 350 mg) daily plus nab-paclitaxel 100 mg/m 2 administered on days 1, 8, and 15 every 28 days. Phase II was according to Simon's two-stage design. PIK3CA mutations in tumor/circulating tumor DNA (ctDNA) were assessed. Primary endpoints were recommended phase II dose (RP2D) and objective response rate (ORR). Additional endpoints included safety, pharmacokinetics, progression-free survival (PFS), and association of PIK3CA mutation with outcomes. Results: A total of 43 patients were enrolled (phase I, n = 13 and phase II, n = 30). A total of 84% had visceral disease and 84% had prior taxane. No dose-limiting toxicities occurred in phase I. RP2D was alpelisib 350 mg daily plus nab-paclitaxel 100 mg/m 2 on days 1, 8, and 15. Hyperglycemia (grade 3, 26% and grade 4, 0%), neutropenia (grade 3, 23% and grade 4, 7%), diarrhea (grade 3, 5% and grade 4, 0%), and rash (grade 3, 7% and grade 4, 0%) were the most common adverse events. Among 42 evaluable patients, ORR was 59% (complete response, 7% and partial response, 52%), 21% of whom had response lasting >12 months; median PFS was 8.7 months. A total of 40% of patients demonstrated tumor and/or ctDNA PIK3CA mutation; patients with tumor/ctDNA mutation demonstrated better PFS compared with those without mutation (11.9 vs. 7.5 months; HR, 0.44; P = 0.027). Patients with normal metabolic status had longer PFS compared with prediabetic/diabetic patients (12 vs. 7.5 months; P = 0.014). No pharmacokinetics interactions were detected. Conclusions: The alpelisib plus nab-paclitaxel combination was well tolerated and shows encouraging efficacy, especially in patients with PIK3CA -mutated tumor/ctDNA. The impact of metabolic status on response to this combination merits further investigation.

oncology
BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer

Giorgio Bogani,Valentina Chiappa,Marta Bini,Dominique Ronzulli,Alice Indini,Elena Conca,Francesco Raspagliesi

DOI: https://doi.org/10.1177/03008916211073621

2022-03-20

Tumori Journal

Abstract:Purpose: Advanced/recurrent cervical cancer has limited therapeutic options, with a median progression-free survival after the failure of systemic treatments ranging between 3.5 and 4.5 months. Here, we reported our preliminary experience in the use of BYL719 (alpelisib) in advanced/recurrent cervical cancer after failure of at least 2 lines of treatment. The Istituto Nazionale dei Tumori di Milano approved this investigation. Methods: From April 2020 to September 2020, 17 consecutive patients with recurrent cervical cancer had Next Generation Sequencing (NGS). Of these, six patients harboring the PIK3CA mutation were included in the study. All patients had been treated with at least 2 previous lines of systemic treatment: 3 patients received >2 prior lines of treatment in the recurrent or metastatic setting; 60% had received prior bevacizumab in combination with chemotherapy. All patients started alpelisib at the daily dosage of 300 mg. Results: Investigator-assessed confirmed objective response rate (ORR) was 33%. The disease control rate (DCR) was 100%. According to RECIST 1.1, two patients had a partial response (PR), and four patients had stable disease (SD). No complete response was observed. The mean duration of response (DOR) was 11.5 (SD 3.75) months; five patients had PR lasting for >9 months. One patient stopped the treatment at 0.82 months due to the onset of a grade 2 adverse event (AE) (skin rash). Grade 3 treatment-related AEs included: lymphoedema (n = 1, 17%) and rash (n = 1, 17%). No treatment-related grade 4-5 AEs occurred. Conclusions: Our preliminary data highlighted a high level of efficacy in this setting of patients. Further trials are needed to assess the safety and effectiveness of alpelisib in PIK3CA-mutated recurrent/advanced cervical cancer.

oncology
Fragment-based treatment of delocalization and static correlation errors in density-functional theory.

J. Nafziger,A. Wasserman

DOI: https://doi.org/10.1063/1.4937771

2013-05-21

Abstract:One of the most important open challenges in modern Kohn-Sham (KS) density-functional theory (DFT) is the correct treatment of systems involving fractional electron charges and spins. Approximate exchange-correlation functionals struggle with such systems, leading to pervasive delocalization and static correlation errors. We demonstrate how these errors, which plague density-functional calculations of bond-stretching processes, can be avoided by employing the alternative framework of partition density-functional theory (PDFT) even using the local density approximation for the fragments. Our method is illustrated with explicit calculations on simple systems exhibiting delocalization and static-correlation errors, stretched H2 (+), H2, He2 (+), Li2 (+), and Li2. In all these cases, our method leads to greatly improved dissociation-energy curves. The effective KS potential corresponding to our self-consistent solutions displays key features around the bond midpoint; these are known to be present in the exact KS potential, but are absent from most approximate KS potentials and are essential for the correct description of electron dynamics.
Preclinical evidence for synergistic effects of autophagy inhibitor and alpelisib in PI3KCA mutated non-small cell lung cancer: Implications for future clinical trials.

Byoung Yong Shim,Sang-Bin Lee,Hyunho Kim,Hyung Soon Park,Ho Jung An

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e21022

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:e21022 Background: The PI3K pathway is frequently activated in a variety of cancers including non-small cell lung cancer (NSCLC). PI3K mutation is associated with worse response to chemotherapy and consequently decrease the effectiveness of single administration of anticancer drugs. In this study, we checked the therapeutic efficacy of alpelisib either alone or in combination with an autophagy inhibitor for the treatment of NSCLC. Methods: We treated alpelisib and autophagy inhibitors in human NSCLC cell lines and measured the cell viability and protein expression of autophagy indicators, p62 and LC3B. Co-treatment of alpelisib and autophagy inhibitors significantly decrease the cell viability and proliferation compared to alpelisib alone. Based on the results of the combination experiment of alpelisib and autophagy inhibitors, Chloroquine (CQ) was selected for further study. Co-treatment of alpelisib and CQ significantly increase apoptosis and decrease tumor-related protein expression in in vitro and in vivo. Results: Our data demonstrates that alpelisib and autophagy inhibitor have a synergistic efficacy against NSCLC in vitro and in vivo. Conclusions: Based on these results, a Phase 1 clinical trial is currently being planned.

oncology
Clinical Response to Neoadjuvant Immunotherapy Combined with Targeted Therapy and Chemotherapy in Oral Squamous Cell Carcinoma: Experience in Three Patients

Yu Tian,Lei Zhang,Nenghao Jin,Zhiyi Wan,Henghui Zhang,Haizhong Zhang,Lei Zhang

DOI: https://doi.org/10.2147/OTT.S355349

IF: 4

2022-04-08

OncoTargets and Therapy

Abstract:Yu Tian, 1, 2, &ast Lei Zhang, 3, &ast Nenghao Jin, 1, 2, &ast Zhiyi Wan, 3 Henghui Zhang, 4, 5 Haizhong Zhang, 2 Lei Zhang 2 1 Department of Stomatology, Medical School of Chinese PLA, Beijing, People's Republic of China; 2 Department of Stomatology, The First Medical Center, Chinese PLA General Hospital, Beijing, People's Republic of China; 3 Department of Medicine, Genecast Biotechnology Co., Ltd, Wuxi, Jiangsu, People's Republic of China; 4 Biomedical Innovation Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China; 5 Ninth School of Clinical Medicine, Peking University, Beijing, China; School of Oncology, Capital Medical University, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Haizhong Zhang; Lei Zhang, Department of Stomatology, The First Medical Center, Chinese PLA General Hospital, No. 28, Fuxing Road, Beijing, People's Republic of China, Tel/Fax +86 1066938316, Email ; Immune checkpoint inhibitors (ICIs) pembrolizumab and nivolumab have been approved for the treatment of head and neck squamous cell carcinoma (HNSCC) and used in neoadjuvant immunotherapy in clinical trials. However, combination of ICIs with targeted therapy and chemotherapy was rarely used in pre-surgical HNSCC patients. Herein, we encountered three cases of patients with oral squamous cell carcinoma (OSCC) who all had good responses to neoadjuvant immunotherapy (anti-PD-1 inhibitors) combined with nimotuzumab (anti-EGFR monoclonal antibody) plus paclitaxel. Both Case 1 and Case 2 underwent the same neoadjuvant therapeutic combination (nivolumab, nimotuzumab and paclitaxel) and exhibited a marked tumor shrinkage even complete disappearance by radiological evaluation. Moreover, pathological response was observed in post-surgical tissues of Case 1. Additionally, Case 3 with tongue squamous cell carcinoma also had satisfactory tumor regression (complete healing of his tongue ulcer upon treatment) after receiving similar neoadjuvant therapy with sintilimab (another PD-1 inhibitor), nimotuzumab and paclitaxel. We characterized their potential causes behind favorable treatment outcomes. While there were differences in driver mutations and tumor mutation burden (TMB) identified in pre-treatment tumor tissues among the three patients, numerous CD68+ (macrophages) infiltrates were common for all the cases. Of note, the majority (> 80%) of the total macrophages were molecularly defined as PD-L1-positive macrophages. Given the high expression of PD-L1 in macrophages is associated with better immunotherapy outcomes, we propose that the high proportion of CD68+PD-L1+ cells in total macrophages alone could serve as a promising biomarker for neoadjuvant immunotherapy in combination with other therapies in HNSCC. Keywords: head and neck squamous cell carcinoma, oral squamous cell carcinoma, neoadjuvant immunotherapy, PD-L1, CD68, macrophage Head and neck cancers usually arise from the squamous cells in oral cavity, oropharynx, hypopharynx, or larynx, being referred to as head and neck squamous cell carcinoma (HNSCC). While patients with locoregionally advanced HNSCC accounting for approximately 60% of all HNSCC cases tend to receive multimodal therapies including surgery and chemoradiotherapy, over half of them experience recurrence. The current first-line standard of care treatment for recurrent or metastatic HNSCC is the combination of cetuximab, platinum and 5-fluorouracil (5-FU), which gives rise to the median overall survival (OS) of less than 10 months. 1 Immune checkpoint inhibitors (ICIs) targeting PD-1 (programmed cell death protein 1) or PD-L1 (programmed death-ligand 1) have revolutionized the treatment paradigm for various cancers. In 2016, two immunotherapeutic agents, PD-1 monoclonal antibodies, nivolumab and pembrolizumab were approved by the US Food and Drug Administration (FDA) for the treatment of patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M HNSCC) refractory to platinum-based therapy. In 2019, the FDA approved pembrolizumab combined with platinum and fluorouracil for the first-line treatment of patients with metastatic or unresectable, recurrent HNSCC, while pembrolizumab monotherapy is indicated for the first-line treatment of PD-L1-positive (CPS > 1) patients with metastatic or unresectable, recurrent HNSCC based on the results of KEYNOTE-048. 2 In addition to immunotherapy, nimotuzumab targeted therapy, an EGFR (epidermal growth factor receptor)-targeted monoclonal IgG1 antibody, has been approved for the treatment of HNSCC in several countries inc -Abstract Truncated-

oncology,biotechnology & applied microbiology
Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors

Ah Reum Lim,Boyeon Kim,Jwa Hoon Kim,Myung Han Hyun,Kyong Hwa Park,Yeul Hong Kim,Soohyeon Lee

DOI: https://doi.org/10.3389/fonc.2024.1390452

IF: 4.7

2024-07-13

Frontiers in Oncology

Abstract:Background: This phase Ib study was performed to determine the safety of combination capecitabine with alpleisib (phosphatidylinositol 3-kinase catalytic subunit p110α blockade) and determine the maximal tolerated dose (MTD) and recommended phase ll dose (RP2D) of this combination regimen in patients with advanced solid tumors refractory to standard therapy. The synergistic anti-tumor activity and pharmacokinetics (PK) were investigated. Methods: Dose escalation phases were conducted in patients with advanced solid cancers who were refractory to standard therapy regardless of PIK3CA mutation. Patients were administered orally once daily alpelisib (200mg and 300mg) and twice daily capecitabine (850mg, 1000mg, 1250mg orally, days 1–14) every 3 weeks. Standard "3 + 3" dose escalation was used to define the MTD. The effect of alpelisib on the PK of capecitabine was assessed. Results: Patients with 6 colorectal cancer (three PIK3CA mutation) and 6 breast cancer (all PIK3CA mutation) were enrolled. The first three patients in dose level 0 (alpelisib 200mg daily, capecitabine 1,000 mg/m 2 twice daily) had no dose-limiting toxicities (DLTs). In dose level 1 (alpelisib increased to 300 mg daily, capecitabine 1,000mg twice daily), one of six patients had DLT (grade (Gr) 3 hyperglycemia). When dose level 2 (alpelisib 300mg daily, capecitabine 1,250 mg/m 2 twice daily) was expanded to 3 patients, no patients had DLTs. The combination of alpelisib 300mg daily and capecitabine 1,250 mg/m 2 twice daily was declared as the MTD/RP2D in patients with advanced solid tumors. The most common AEs were Gr 1–3 hyperglycemia (75.0%). Frequent all-grade, treatment-related AEs included Gr 2–3 nausea (75.0%), Gr 1–2 diarrhea (50.0%), Gr 1–2 hand-foot syndrome (41.7%), Gr 1–2 anorexia (41.7%), Gr 2 mucositis (33.3%). Antitumor activity was observed in patients with PIK3CA mutant breast cancer (3 partial response and 3 stable disease of total 6 patients). Alpelisib exposure (C max and AUC 0-12 ) was unaffected by concomitant capecitabine. There were no clinically relevant drug-drug interactions observed between alpelisib and capecitabine. Conclusions: The combination of alpelisib and capecitabine is generally tolerated, without pharmacokinetic interactions, and shows antitumor activity in patients with PIK3CA mutant advanced cancers.

oncology
Time and direction of arrival detection and filtering for imaging in strongly scattering random media

L. Borcea,G. Papanicolaou,C. Tsogka

DOI: https://doi.org/10.1080/17455030.2017.1303220

2016-03-16

Abstract:We study detection and imaging of small reflectors in heavy clutter, using an array of transducers that emits and receives sound waves. Heavy clutter means that multiple scattering of the waves in the heterogeneous host medium is strong and overwhelms the arrivals from the small reflectors. Building on the adaptive time-frequency filter of [Borcea et al, SIIMS 2011;4(3)], we propose a robust method for detecting the direction of arrival of the direct echoes from the small reflectors, and suppressing the unwanted clutter backscatter. This improves the resolution of imaging. We illustrate the performance of the method with realistic numerical simulations in a non-destructive testing setup.
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma

Nicole L. Michmerhuizen,Elizabeth Leonard,Chloe Matovina,Micah Harris,Gabrielle Herbst,Aditi Kulkarni,Jingyi Zhai,Hui Jiang,Thomas E. Carey,J. Chad Brenner

DOI: https://doi.org/10.1124/mol.118.115162

2019-01-01

Molecular Pharmacology

Abstract:Head and neck squamous cell carcinoma (HNSCC) is a common and debilitating form of cancer characterized by poor patient outcomes and low survival rates. In HNSCC, genetic aberrations in phosphatidylinositol 3-kinase (PI3K) and epidermal growth factor receptor (EGFR) pathway genes are common, and small molecules targeting these pathways have shown modest effects as monotherapies in patients. Whereas emerging preclinical data support the combined use of PI3K and EGFR inhibitors in HNSCC, in-human studies have displayed limited clinical success so far. Here, we examined the responses of a large panel of patient-derived HNSCC cell lines to various combinations of PI3K and EGFR inhibitors, including EGFR agents with varying specificity and mechanistic characteristics. We confirmed the efficacy of PI3K and EGFR combination therapies, observing synergy with α isoform-selective PI3K inhibitor HS-173 and irreversible EGFR/ERBB2 dual inhibitor afatinib in most models tested. Surprisingly, however, our results demonstrated only modest improvement in response to HS-173 with reversible EGFR inhibitor gefitinib. This difference in efficacy was not explained by differences in ERBB target selectivity between afatinib and gefitinib; despite effectively disrupting ERBB2 phosphorylation, the addition of ERBB2 inhibitor CP-724714 failed to enhance the effect of HS-173 gefitinib dual therapy. Accordingly, although irreversible ERBB inhibitors showed strong synergistic activity with HS-173 in our models, none of the reversible ERBB inhibitors were synergistic in our study. Therefore, our results suggest that the ERBB inhibitor mechanism of action may be critical for enhanced synergy with PI3K inhibitors in HNSCC patients and motivate further preclinical studies for ERBB and PI3K combination therapies.
Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy

Ari J Rosenberg,Cesar A Perez,Wenji Guo,Jose Monteiro de Oliveira Novaes,Kamilla F Oliveira da Silva Reis,Patrick W McGarrah,Katharine A R Price

DOI: https://doi.org/10.1200/EDBK_433330

Abstract:The treatment for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) with immune checkpoint inhibitors (anti-PD1) with or without chemotherapy has led to an improvement in survival. Yet, despite this therapeutic advancement, only 15%-19% of patients remain alive at four years, highlighting the poor survival and unmet need for improved therapies for this patient population. Some of the key evolving novel therapeutics beyond anti-PD1 in R/M HNSCC have included therapeutic vaccine therapies, bispecific antibodies/fusion proteins and multitargeted kinase inhibitors, and antibody-drug conjugates (ADCs). Multiple concurrent investigations of novel therapeutics for patients with R/M HNSCC beyond anti-PD(L)1 inhibition are currently underway with some promising early results. Beyond immune checkpoint inhibition, novel immunotherapeutic strategies including therapeutic vaccines ranging from targeting human papillomavirus-specific epitopes to personalized neoantigen vaccines are ongoing with some early efficacy signals and large, randomized trials. Other novel weapons including bispecific antibodies, fusion proteins, and multitargeted kinase inhibitors leverage multiple concurrent targets and modulation of the tumor microenvironment to harness antitumor immunity and inhibition of protumorigenic signaling pathways with emerging promising results. Finally, as with other solid tumors, ADCs remain a promising therapeutic intervention either alone or in combination with immunotherapy for patients with R/M HNSCC. With early enthusiasm across novel therapies in R/M HNSCC, results of larger randomized trials in R/M HNSCC are eagerly awaited.
Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.

Hsiang-fong Kao,Bin-Chi Liao,Yen-Lin Huang,Huai-Cheng Huang,Chun-Nan Chen,Tseng-Cheng Chen,Yuan-Jing Hong,Ching-Yi Chan,Ruey-Long Hong

DOI: https://doi.org/10.1200/jco.2021.39.15_suppl.6024

IF: 45.3

2021-05-20

Journal of Clinical Oncology

Abstract:6024 Background: Epidermal growth factor receptor (EGFR) pathway inhibition may synergize with anti-PD1 activity by inhibiting macrophage function, increasing antigen presentation, and augmenting T cell responses. Afatinib, an irreversible EGFR tyrosine kinase inhibitor (TKI), has been shown to enhance anti-PD1 activity in in vitro and animal studies. We thus hypothesized that adding afatinib to pembrolizumab may improve the treatment outcomes for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Methods: The ALPHA study (NCT03695510) is a single-arm, phase II study with a Simon 2-stage design. Patients with platinum-refractory, recurrent, or metastatic HNSCC are eligible for the study. Afatinib (40mg, oral, daily) and pembrolizumab (200mg, every 3 weeks) are administered to eligible patients. The primary endpoint is the objective response rate (ORR). PD-L1 IHC testing (22C3), comprehensive genomic profiling (CGP, Roche Foundation Medicine One CDx), and targeted multiplexed gene expression profiling (Nanostring nCounter PanCancer Immune Profiling Panel) were applied for biomarker analysis. Results: From JAN 2019 to MAR 2020, 29 patients were enrolled in the study. Age: mean = 53.4 years old; M/F = 27/2. Tumor type: oral cavity: 19; oropharynx: 6, hypopharynx: 2, larynx: 2. PD-L1 TPS > = 50: 7/29 (24.1%), CPS > = 20: 8/29 (27.6%), TMB > 10: 0/25 (0%). The common treatment-related adverse events (AEs; all grades, grade > = 3) were skin rash (22/29, 4/29), diarrhea (17/29, 3/29), paronychia (13/29, 0/29), mucositis (9/29, 1/29), and weight loss (2/29, 0/29). One patient experienced grade 2 pneumonitis. Twelve patients had partial responses to the treatment (12/29, ORR: 41.4%). The data cut-off date was 11FEB2021. The median progression free survival (PFS) was 4.1 (95% confidence interval [CI], 1.9-6.3) months. The median overall survival (OS) was 8.4 (95% CI, 4.1-10.8) months. Patients with high PD-L1 expression had a higher response rate (TPS > = 50: ORR = 0.71, CPS > = 20: ORR = 0.63). EGFR amplification might also predict a higher response rate (ORR: 3/3, 100%). MTAP loss or mutation may predict a poor response to the treatment (ORR: 0/5, 0%), shorter PFS (HR: 4.21, [95% CI: 1.34-13.24], p = 0.014), and shorter OS (HR: 4.20 [95% CI: 1.32-13.41], p = 0.015). Nine patients underwent paired pre-treatment and post-treatment biopsies for gene expression analysis. The mRNA of HLA-A, HLA-B, CXCL13, CXCL9, and CD8A were elevated in the post-treatment biopsies. Three patients underwent post-progression biopsies for CGP study. One patient had a new MTAP mutation. Conclusions: Afatinib can modify tumor microenvironment and increase the clinical response rate in pembrolizumab-based therapy in HNSCC patients. PD-L1, EGFR amplification, and MTAP loss/mutation could be biomarkers for cancer immunotherapy. Clinical trial information: NCT03695510.

oncology
Pembrolizumab and Cabozantinib in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma (RMHNSCC): 2-year Long Term Survival Update with Biomarker Analysis

N.F. Saba,A. Ekpenyong,A. McCook,N.C. Schmitt,J.H. Gross,S.F. Rudra,W.A. Stokes,K. Kirtane,R. Chaudhary,M. Biernacki,R. Slebos,X. Song,C. Steuer,D.M. Shin,Y.F. Teng,Y. Liu,C.H. Chung

DOI: https://doi.org/10.1016/j.ijrobp.2024.01.017

IF: 8.013

2024-04-01

International Journal of Radiation Oncology*Biology*Physics

Abstract:Purpose/Objective(s) Anti-programmed cell death protein 1 (PD-1) therapy is a standard of care in recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC). Vascular endothelial growth factor receptor tyrosine kinase inhibitors have immunomodulatory properties and may improve clinical outcomes in combination with anti-PD-1 therapy. Pembrolizumab and cabozantinib were well tolerated and showed promising clinical activity in patients with RMHNSCC in our reported phase 2 trial. Baseline CD8+ T cell infiltration correlated with overall response rate (ORR) (p=0.0512). We report 2-year follow-up results focusing on long-term efficacy and safety of this combination as well as further biomarker analyses. Materials/Methods This open label, single arm, multicenter, phase 2 study screened 50 patients with RMHNSCC, of whom 36 received pembrolizumab and cabozantinib. The primary endpoint was (ORR) as well as safety and tolerability. Secondary endpoints included PFS, OS, and correlative studies of tissue and blood. We report the 2-yr long term efficacy and safety of this regimen. Multiplex immunohistochemistry staining for CD3, CD8, CD20, and CD103+ cells, as well as hypoxia gene expression signature were evaluated and correlated with ORR, PFS and OS. Results With a median follow-up of 22.4 months (95%CI 19.2-31.8), 14 pts (38.9%) remain alive with 7 pts (19.4%) having no disease progression and 1 pt (2.8%) with no evidence of disease. One pt continues on treatment. Median PFS was 12.8 mos., with 1-yr PFS of 53.2% (95% CI 38.8-72.9%) and 2-yr PFS of 32.6 % (95% CI 18.8-56.3%). Median OS was 27.7 mos, with 1-yr OS of 73.8% (95% CI 60.4-90.1%) and 2-yr OS of 54.7% (95% CI 38.9-76.8%). Median duration of response is 12.6 mos, with 2-yr rate of 38.5% (95% CI 30.8-81.8%). Most common grade 3-4 treatment-related adverse events (TRAEs) included AST increase and oral mucositis (5.6%); ALT, bilirubin, GGT, and lipase increase (2.8% each); and hyponatremia (2.8%). TRAEs persisting beyond 12 months from enrollment include hypothyroidism (5.6%) and increased AST and ALT (5.6%). The higher median number of tumor-infiltrating CD103+ cells correlated with improved OS (HR=0.15, p=0.007). Conclusion Long-term results of our phase II pembrolizumab and cabozantinib study in RMHNSCC demonstrate encouraging 2-yr PFS and OS and maintaining manageable safety profiles. Our findings support further investigation of this combinatorial regimen in a confirmatory randomized trial. Evaluation of CD103 + cells as a predictive biomarker deserves further validation.

oncology,radiology, nuclear medicine & medical imaging
Sintilimab combined with anlotinib as first-line treatment for advanced sarcomatoid carcinoma of head and neck: a case report and literature review

Lei Wang,Yingyu Huang,Xin Sun

DOI: https://doi.org/10.3389/fonc.2024.1362160

IF: 4.7

2024-04-25

Frontiers in Oncology

Abstract:Sarcomatoid carcinoma (SC) is a rare, complex, aggressive tumor that spreads rapidly, is highly malignant, and has metastasized. Surgical resection is the primary treatment, and it usually occurs in the lungs and kidneys but rarely in the neck. Patients with advanced sarcomatoid carcinoma (SC) of the head and neck (HN) have a poor progonsis. In recent years, immune checkpoint inhibitors (ICIs) have been established as treatments for many solid tumors; however, the effectiveness of ICIs in treating SC of HN is still little recognized. We report a case study of a middle-aged woman with primary sarcomatoid carcinoma of the neck. She developed sarcomatoid carcinoma of the contralateral neck 7 months after the first surgical treatment. Subsequently, disease recurrence and metastasis occurred 8 months after the second surgery. The patient did not receive any treatment after both surgeries. The tumor showed high programmed death-ligand 1 (PD-L1) expression, with a combined positive score (CPS): 95. The patient's response to treatment was assessed as partial remission (PR) after 2 cycles of anlotinib combined with sintilimab. The patient has survived for over 2 years and remains in PR status, despite experiencing grade 2 hypothyroidism as an adverse event during treatment. The case highlights the efficacy and safety of anlotinib and sintilimab as a first-line treatment.

oncology
PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights

Sreeja Sreekumar,Elodie Montaudon,Davis Klein,Migdalia E. Gonzalez,Pierre Painsec,Héloise Derrien,Laura Sourd,Tod Smeal,Elisabetta Marangoni,Maya Ridinger

DOI: https://doi.org/10.3390/cancers16193259

2024-09-26

Cancers

Abstract:Background: Endocrine therapy (ET) combined with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) is the preferred first-line treatment for hormone receptor-positive (HR+)/HER2- metastatic breast cancer. Although this is beneficial, acquired resistance leads to disease progression, and patients harboring PIK3CA mutations are treated with targeted therapies such as the PI3Kα inhibitor, alpelisib, alongside ET. Drug-associated resistance mechanisms limit the efficacy of alpelisib, highlighting the need for better combination therapies. This study aimed to evaluate the efficacy of combining alpelisib with a highly specific PLK1 inhibitor, onvansertib, in PIK3CA-mutant HR+ breast cancer preclinical models. Methods: We assessed the effect of the alpelisib and onvansertib combination on cell viability, PI3K signaling pathway, cell cycle phase distribution and apoptosis in PI3K-activated HR+ breast cancer cell lines. The antitumor activity of the combination was evaluated in three PIK3CA-mutant HR+ breast cancer patient-derived xenograft (PDX) models, resistant to ET and CDK4/6 inhibitor palbociclib. Pharmacodynamics studies were performed using immunohistochemistry and Simple Western analyses in tumor tissues. Results: The combination synergistically inhibited cell viability, suppressed PI3K signaling, induced G2/M arrest and apoptosis in PI3K-activated cell lines. In the three PDX models, the combination demonstrated superior anti-tumor activity compared to the single agents. Pharmacodynamic studies confirmed the inhibition of both PLK1 and PI3K activity and pronounced apoptosis in the combination-treated tumors. Conclusions: Our findings support that targeting PLK1 and PI3Kα with onvansertib and alpelisib, respectively, may be a promising strategy for patients with PIK3CA-mutant HR+ breast cancer failing ET + CDK4/6i therapies and warrant clinical evaluation.

oncology
Abstract CT047: A phase 2 study of ipatasertib in combination with pembrolizumab for first line treatment of recurrent or metastatic squamous cell cancer of the head and neck

Jacob S. Thomas,Robert Hsu,Victoria Villaflor,Jonathan Riess,Jorge Nieva,Mark Krailo,Silvio Gutkind,Dimitri Colevas

DOI: https://doi.org/10.1158/1538-7445.am2023-ct047

IF: 11.2

2023-04-20

Cancer Research

Abstract:Background: Single agent pembrolizumab in relapsed/metastatic head and neck squamous cell carcinoma (R/M HNSCC) has an ORR of 19% and mOS of 13.6 months. There are many factors which may influence which patients respond to antibodies targeting the PD-1 axis. Regulatory T cells (Tregs) play a significant role in an immunosuppressive tumor microenvironment (TME). Low Tregs in the TME have been correlated with clinical efficacy with PD-1 blockade in various solid tumors. Tregs play an active role in HNSCC. Anti-PD-1 antibodies induce Treg activation in part through AKT pathway activation, which may contribute to low response rates to checkpoint inhibitor therapy. AKT blockade selectively inhibits the proliferation of human Tregs. Additionally, inhibition of the PI3K-AKT-mTOR pathway limits myeloid-derived suppressor cells (MDSC) infiltration and differentiation, and boosts CD8+ T cell memory and effector function. Ipatasertib is an oral highly selective small-molecule inhibitor of all three isoforms of AKT. In the Ice-CAP phase I solid tumor trial, combination PD-L1 antibody and Ipatasertib demonstrated reduction of Tregs and increased CD8+ effector T cells in paired biopsy specimens. This trial is designed to compare the efficacy of combination ipatasertib plus pembrolizumab compared to pembrolizumab monotherapy in R/M HNSCC. Methods: In this prospective, two-arm, phase II, multicenter trial, patients with R/M HNSCC will be treated with pembrolizumab 200mg on day 1 with or without ipatasertib 400mg QD days 1-14 of 21-day cycles. Patients must have PD-L1 CPS score ≥ 1, have measurable disease per RECIST 1.1, and consent to on-treatment biopsy. Patients will be excluded if they have received prior systemic therapy for R/M HNSCC, cannot swallow a pill, or require insulin for diabetes. The primary objective is to compare the PFS between the two arms. We will estimate the relative hazard ratio associated with Ipatasertib plus pembrolizumab compared to pembrolizumab using the Cox Model where randomized treatment assignment is the only variable in the model. A total of 48 patients will be enrolled, with 24 patients in each cohort. Secondary objectives include ORR, safety and tolerability of the combination, and changes in tumor immune cell infiltration, AKT signaling, and changes in peripheral blood immune cells. Accrual is ongoing (NCT05172258). Citation Format: Jacob S. Thomas, Robert Hsu, Victoria Villaflor, Jonathan Riess, Jorge Nieva, Mark Krailo, Silvio Gutkind, Dimitri Colevas. A phase 2 study of ipatasertib in combination with pembrolizumab for first line treatment of recurrent or metastatic squamous cell cancer of the head and neck [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl) nr CT047.

oncology
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

Marcin Dzienis,Juan Cundom,Christian Sebastian Fuentes,Anna Spreafico,Melanie Nordlinger,Andrea Viviana Pastor,Erin Alesi,Anterpreet Neki,Andrea S Fung,Iane Pinto Figueiredo Lima,Peter Oppelt,Geraldo Felicio da Cunha Junior,Barbara Burtness,Fabio Andre Franke,Jennifer E Tseng,Abhishek Joshi,Joy McCarthy,Ramona Swaby,Yulia Sidi,Burak Gumuscu,Niroshini Naicker,Gilberto de Castro Jr

DOI: https://doi.org/10.1200/JCO.23.02625

2024-09-01

Abstract:Purpose: Standard-of-care first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) is pembrolizumab plus platinum and fluorouracil (FU). However, FU is associated with potential challenges (continuous 4-day infusion, high administration costs, and cardiovascular and gastrointestinal toxicities), creating a clinical need for alternative chemotherapy combinations. We evaluated the efficacy and safety of first-line pembrolizumab plus carboplatin and paclitaxel for R/M HNSCC in the open-label, single-arm, phase IV KEYNOTE-B10 study (ClinicalTrials.gov identifier: NCT04489888). Methods: Eligible adults had previously untreated, histologically or cytologically confirmed R/M HNSCC regardless of PD-L1 status, measurable disease per RECIST v1.1 by blinded independent central review (BICR), and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received pembrolizumab 200 mg intravenously once every 3 weeks for ≤35 cycles and carboplatin AUC 5 mg/mL/min intravenously once every 3 weeks for ≤6 cycles and investigator's choice of paclitaxel 100 mg/m2 on days 1 and 8 or 175 mg/m2 on day 1, intravenously once every 3 weeks. The primary end point was objective response rate per RECIST v1.1 by BICR. Results: Between October 27, 2020, and April 29, 2022, 149 patients were screened and 101 received treatment. As of February 20, 2023, the median follow-up was 18.9 months (range, 9.1-27.0). At this final analysis, 49 (49%) of 101 patients had an objective response (95% CI, 38.4 to 58.7), including seven patients (7%) with a confirmed complete response. Of the 101 treated patients, grade 3-5 and serious treatment-related adverse events occurred in 76 (75%) and 27 (27%), respectively. There were no new safety signals. Conclusion: Pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity and a manageable safety profile in first-line R/M HNSCC, suggesting this combination may be an alternative option for this patient population.
Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score ≥ 2: a retrospective study

Wen-Jie Wu,Pu-Gen An,Yi-Wei Zhong,Xiao Hu,Lin Wang,Jie Zhang

DOI: https://doi.org/10.3389/fonc.2023.1273798

IF: 4.7

2024-01-17

Frontiers in Oncology

Abstract:Objectives: The efficacy of treatments targeting recurrent or metastatic head and neck squamous cell carcinoma are unsatisfactory in practice for patients with a ECOG PS score ≥ 2. Thus, this study retrospectively evaluated the safety and efficacy of a programmed cell death 1 inhibitor (tislelizumab) combined with an epidermal growth factor receptor inhibitor (nimotuzumab) in treating patients with a PS score ≥ 2 who suffer from recurrent or metastatic oral squamous cell carcinoma (OSCC). Materials and methods: Fifteen patients were treated with tislelizumab (200 mg IV Q3W) and nimotuzumab (200 mg IV Q3W). Programmed cell death-ligand 1 (PD-L1) expression in tumor biopsies was assessed with immunohistochemistry. Whole-exome sequencing was used to evaluate treatment efficacy based on PD-L1 expression and gene mutation. Results: At a median follow-up of 9.6 months, median overall survival was 10.1 months, and median progression-free survival was 4.0 months. Overall response rate was 40%, with 6/15 patients achieving partial response. Eight patients exhibited nine adverse events, eight out of nine being grade 2 and the remaining being grade 3. Whole-exome sequencing showed that DYNC1I2, THSD7A , and FAT1 mutations were associated with patient prognosis. Conclusion: Combination therapy involving tislelizumab plus nimotuzumab is a promising, low-toxicity treatment for recurrent or metastatic OSCC in patients with a PS score ≥ 2.

oncology
Neoadjuvant Pembrolizumab/nab-Paclitaxel/cisplatin in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase II Study.

Siyi Zhang,Haiqing Ma,Jiandong Zhan,Lijun Zhu,Hong-Dan Zhang,Shasha Du,Qiumei Dong,Guangyi Wang

DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.e18043

IF: 45.3

2024-01-01

Journal of Clinical Oncology

Abstract:e18043 Background: Despite multimodality standard therapy, patients with locally advanced head and neck squamous cell carcinoma are at high risk of recurrence and distant metastasis. The safety and efficacy of immunotherapy (pembrolizumab) has been reported in patients with recurrent/metastatic HNSCC. We hypothesized that neoadjuvant chemo-immunotherapy has a positive effect on decreasing distant metastasis, preserving organ function and extending survival time. Methods: In this prospective, non-randomized, single-arm phase II clinical trial, patients meeting the inclusion criteria were treated neoadjuvant therapy with 200 mg pembrolizumab combined with 75 mg/m2 cisplatin and 260 mg/m2 Nab-paclitaxel per 3 weeks for 2 cycles.Patients will undergo the first radiologic imaging assessment after neoadjuvant therapy. After multi-disciplinary team discussion, patients with Partial Response (PR) but the maximum diameter of tumor > 3cm or stable disease (SD) or progressive disease (PD) receive surgery and standard adjuvant therapy. On the other hand, patients with PR and maximum tumor diameter ≤ 3cm or Complete Response (CR) receive definitive CRT. Evaluation was performed 3 months after definitive CRT and patients with high-risk factors need maintenance treatment. Primary outcomes are objective response rate (ORR), safety, rate of organ preservation. Results: A total of 31 patients were enrolled with a median follow-up of 6.6 months (1.4-20.2m). The baseline characteristics were shown in the table. Among 31 LA HNSCC patients with 2 cycles of neoadjuvant therapy, ORR was 64.52% (20/31) and DCR was 100%. 10patients underwent surgery with R0 resection, and 17 patients received definitive CRT,4 patients refuse surgery or CRT and out of trial. There was 20/31 (64.5%) organ function preservation. Among those with definitive CRT, no recurrence or distant metastasis occurred. In this trial, there's no Grade≥3 treatment-related adverse events. One patient died due to cardiacarrest and the correlation with study cannot be evaluated. Conclusions: Neoadjuvant chemo-immunotherapy contributed to good ORR and organ function preservation, and generally tolerated in LA HNSCC. This study is ongoing. And we look forward to demonstrating that neoadjuvant immunochemotherapy is expected to improve long-term survival of LA-HNSCC. Clinical trial information: NCT05272696 . [Table: see text]
Abstract 322: Discovery of Synergistic PI3K Inhibitor Combination Therapies Using High Throughput Approaches in HNSCC

Nicole Lynn Michmerhuizen,Elizabeth Leonard,Caitlin Heenan,Vivek Nair,Chloe Matovina,Micah Harris,Gabrielle Herbst,Daniel Kim,Amanda Bachand,Jingyi Zhai,Susan K. Foltin,Aditi Kulkarni,Thomas E. Carey,Carol R. Bradford,Hui Jiang,John C. Brenner

DOI: https://doi.org/10.1158/1538-7445.sabcs18-322

IF: 11.2

2019-01-01

Cancer Research

Abstract:Recent head and neck squamous cell carcinoma (HNSCC) sequencing studies have identified the phosphatidylinositol 3-kinase (PI3K) pathway as the most frequently mutated, oncogenic pathway in this cancer type. Despite frequent activating mutation or amplification in PIK3CA (the gene encoding the catalytic subunit of PI3K), targeted PI3K inhibitors have shown limited clinical efficacy as monotherapies. To identify factors that might predict sensitivity and resistance to PI3K inhibitors, we tested a panel of more than 40 patient-derived HNSCC cell lines and observed varying sensitivity to PI3K inhibitors. While all cell lines were much more sensitive than fibroblasts to these drugs, responses varied widely; for pan-PI3K inhibitor BKM120, IC50 values ranged from 0.2 to 4.2 μM across the OSCC cell line panel. Responses to BKM120 do not correlate with PIK3CA mutation status copy number, RNA expression, p110α protein levels, and AKT phosphorylation at baseline and after inhibitor treatment, among other genetic or phenotypic features.In order to characterize potential mechanisms of PI3K inhibitor resistance in HNSCC, we have also developed and optimized an unbiased, high-throughput screening approach. We have used this assay to test ~1400 inhibitors as monotherapies and in combination with PI3K inhibitors HS-173 and BKM120 in ten HNSCC models. Our initial screening data suggested that combinations of PI3K inhibitors and ALK inhibitors are among the most synergistic in a subset of cell lines. We have evaluated the effects of these drug combinations on apoptosis, cell cycle, and downstream signaling in several in vitro HNSCC models, observing synergy in response to FDA-approved agents PI3K inhibitor pictilisib and ALK inhibitor brigatinib in various systems using a range of techniques. We next plan to expand these analyses to organoid and xenograft models to evaluate their effects in more clinically relevant settings.Future studies will also examine additional factors that may predict PI3K inhibitor responses and will seek to better understand promising combination treatments and advance them for effective use in HNSCC patients.Citation Format: Nicole Lynn Michmerhuizen, Elizabeth Leonard, Caitlin Heenan, Vivek Nair, Chloe Matovina, Micah Harris, Gabrielle Herbst, Daniel Kim, Amanda Bachand, Jingyi Zhai, Susan K. Foltin, Aditi Kulkarni, Thomas E. Carey, Carol R. Bradford, Hui Jiang, John C. Brenner. Discovery of synergistic PI3K inhibitor combination therapies using high throughput approaches in HNSCC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 322.

Pleomorphic adenoma of Krause's gland in lower lid.

Combination of Anlotinib and Sintilimab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: a Single-Arm Prospective Study

Basal cell carcinoma, syringocystadenoma papilliferum, trichilemmoma, and sebaceoma arising within a nevus sebaceus associated with pigmented nevi.

Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer

Fragment-based treatment of delocalization and static correlation errors in density-functional theory.

Preclinical evidence for synergistic effects of autophagy inhibitor and alpelisib in PI3KCA mutated non-small cell lung cancer: Implications for future clinical trials.

Clinical Response to Neoadjuvant Immunotherapy Combined with Targeted Therapy and Chemotherapy in Oral Squamous Cell Carcinoma: Experience in Three Patients

Phase Ib and pharmacokinetics study of alpelisib, a PIK3CA inhibitor, and capecitabine in patients with advanced solid tumors

Time and direction of arrival detection and filtering for imaging in strongly scattering random media

Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma

Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy

Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.

Pembrolizumab and Cabozantinib in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma (RMHNSCC): 2-year Long Term Survival Update with Biomarker Analysis

Sintilimab combined with anlotinib as first-line treatment for advanced sarcomatoid carcinoma of head and neck: a case report and literature review

PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights

Abstract CT047: A phase 2 study of ipatasertib in combination with pembrolizumab for first line treatment of recurrent or metastatic squamous cell cancer of the head and neck

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

Tislelizumab plus nimotuzumab is effective against recurrent or metastatic oral squamous cell carcinoma among patients with a performance status score ≥ 2: a retrospective study

Neoadjuvant Pembrolizumab/nab-Paclitaxel/cisplatin in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma: A Single-Arm Phase II Study.

Abstract 322: Discovery of Synergistic PI3K Inhibitor Combination Therapies Using High Throughput Approaches in HNSCC